Identification of early biomarkers in saliva in genetically engineered mouse model C(3)1-TAg of breast cancer
© 2022. The Author(s)..
Breast cancer is one of leading causes of death worldwide in the female population. Deaths from breast cancer could be reduced significantly through earlier and more efficient detection of the disease. Saliva, an oral fluid that contains an abundance of protein biomarkers, has been recognized as a promising diagnostic biofluid that is easy to isolate through non-invasive techniques. Assays on saliva can be performed rapidly and are cost-effective. Therefore, our work aimed to identify salivary biomarkers present in the initial stages of breast cancer, where cell alterations are not yet detectable by histopathological analysis. Using state-of-the-art techniques, we employed a transgenic mouse model of mammary cancer to identify molecular changes in precancerous stage breast cancer through protein analysis in saliva. Through corroborative molecular approaches, we established that proteins related to metabolic changes, inflammatory process and cell matrix degradation are detected in saliva at the onset of tumor development. Our work demonstrated that salivary protein profiles can be used to identify cellular changes associated with precancerous stage breast cancer through non-invasive means even prior to biopsy-evident disease.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Scientific reports - 12(2022), 1 vom: 07. Juli, Seite 11544 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gilson Sena, Isadora Fernandes [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 11.07.2022 Date Revised 15.09.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41598-022-14514-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM343193388 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM343193388 | ||
003 | DE-627 | ||
005 | 20231226204940.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41598-022-14514-1 |2 doi | |
028 | 5 | 2 | |a pubmed24n1143.xml |
035 | |a (DE-627)NLM343193388 | ||
035 | |a (NLM)35798767 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gilson Sena, Isadora Fernandes |e verfasserin |4 aut | |
245 | 1 | 0 | |a Identification of early biomarkers in saliva in genetically engineered mouse model C(3)1-TAg of breast cancer |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.07.2022 | ||
500 | |a Date Revised 15.09.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a Breast cancer is one of leading causes of death worldwide in the female population. Deaths from breast cancer could be reduced significantly through earlier and more efficient detection of the disease. Saliva, an oral fluid that contains an abundance of protein biomarkers, has been recognized as a promising diagnostic biofluid that is easy to isolate through non-invasive techniques. Assays on saliva can be performed rapidly and are cost-effective. Therefore, our work aimed to identify salivary biomarkers present in the initial stages of breast cancer, where cell alterations are not yet detectable by histopathological analysis. Using state-of-the-art techniques, we employed a transgenic mouse model of mammary cancer to identify molecular changes in precancerous stage breast cancer through protein analysis in saliva. Through corroborative molecular approaches, we established that proteins related to metabolic changes, inflammatory process and cell matrix degradation are detected in saliva at the onset of tumor development. Our work demonstrated that salivary protein profiles can be used to identify cellular changes associated with precancerous stage breast cancer through non-invasive means even prior to biopsy-evident disease | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a Salivary Proteins and Peptides |2 NLM | |
700 | 1 | |a Fernandes, Larissa Lessi |e verfasserin |4 aut | |
700 | 1 | |a Lorandi, Leonardo Lima |e verfasserin |4 aut | |
700 | 1 | |a Santana, Thais Viggiani |e verfasserin |4 aut | |
700 | 1 | |a Cintra, Luciana |e verfasserin |4 aut | |
700 | 1 | |a Lima, Ismael Feitosa |e verfasserin |4 aut | |
700 | 1 | |a Iwai, Leo Kei |e verfasserin |4 aut | |
700 | 1 | |a Kramer, Jill M |e verfasserin |4 aut | |
700 | 1 | |a Birbrair, Alexander |e verfasserin |4 aut | |
700 | 1 | |a Heller, Débora |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 07. Juli, Seite 11544 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:07 |g month:07 |g pages:11544 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-022-14514-1 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2022 |e 1 |b 07 |c 07 |h 11544 |